Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Cash & Equivalents (2020 - 2026)

RxSight filings provide 6 years of Cash & Equivalents readings, the most recent being $19.9 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 91.59% to $19.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.9 million, a 91.59% decrease, with the full-year FY2025 number at $19.9 million, down 91.59% from a year prior.
  • Cash & Equivalents hit $19.9 million in Q4 2025 for RxSight, down from $227.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $237.2 million in Q4 2024 to a low of $8.8 million in Q2 2023.
  • Median Cash & Equivalents over the past 5 years was $107.9 million (2022), compared with a mean of $103.9 million.
  • Biggest five-year swings in Cash & Equivalents: crashed 92.43% in 2022 and later surged 1260.65% in 2025.
  • RxSight's Cash & Equivalents stood at $156.4 million in 2021, then crashed by 92.43% to $11.8 million in 2022, then surged by 974.87% to $127.2 million in 2023, then skyrocketed by 86.48% to $237.2 million in 2024, then tumbled by 91.59% to $19.9 million in 2025.
  • The last three reported values for Cash & Equivalents were $19.9 million (Q4 2025), $227.5 million (Q3 2025), and $223.5 million (Q2 2025) per Business Quant data.